| scholarly article | Q13442814 |
| P50 | author | Andrew D Zelenetz | Q46643038 |
| Steven M Horwitz | Q85620133 | ||
| P2093 | author name string | Heiko Schöder | |
| Carla Casulo | |||
| Jocelyn Maragulia | |||
| Remy Lim | |||
| John Feeney | |||
| P2860 | cites work | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas | Q34102089 |
| Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma | Q36836092 | ||
| F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas | Q36911500 | ||
| Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review | Q37410731 | ||
| Characterization of T-cell lymphomas by FDG PET/CT. | Q37774812 | ||
| Role of functional imaging in the management of lymphoma | Q37863991 | ||
| 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution | Q40735816 | ||
| Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. | Q42927507 | ||
| Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas | Q43222216 | ||
| Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease | Q43545833 | ||
| Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma | Q44114749 | ||
| The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma | Q44656144 | ||
| Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas. | Q44750186 | ||
| Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck | Q46312535 | ||
| [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. | Q46463095 | ||
| FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. | Q46568257 | ||
| Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies | Q46569950 | ||
| Revised response criteria for malignant lymphoma | Q47582438 | ||
| Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. | Q51646044 | ||
| Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. | Q53162508 | ||
| Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. | Q53170372 | ||
| Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. | Q53186085 | ||
| 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. | Q53276101 | ||
| CT and PET/CT findings of T-cell lymphoma. | Q53343142 | ||
| Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma | Q73931554 | ||
| FDG-PET in T-cell and NK-cell neoplasms | Q80837973 | ||
| P433 | issue | 10 | |
| P921 | main subject | positron emission tomography | Q208376 |
| P304 | page(s) | 2163-2167 | |
| P577 | publication date | 2013-03-04 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma | |
| P478 | volume | 54 |
| Q92560114 | 18F-FDG PET/CT imaging findings in anaplastic large cell lymphoma, a rare subtype of lymphoma |
| Q52782304 | Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue. |
| Q89749871 | Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial |
| Q60907239 | Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma |
| Q50736205 | Clinical usefulness of FDG-PET/CT for the evaluation of various types of adult T-cell leukemia. |
| Q38836081 | FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas |
| Q38345572 | Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. |
| Q39098289 | Non-anaplastic peripheral T-cell lymphoma in children and adolescents--a retrospective analysis of the NHL-BFM study group |
| Q48328481 | Positron emission tomography computed tomography features of monomorphic epitheliotropic intestinal T-cell lymphoma |
| Q34908079 | Potential role of (18)F-2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography imaging in patients presenting with generalized lymphadenopathy. |
| Q26771059 | Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma |
| Q35224833 | Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas |
| Q35232775 | Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma |
| Q33829759 | Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. |
| Q49894028 | Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation |
| Q37240835 | Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. |
| Q35685336 | Survival in patients with limited-stage peripheral T-cell lymphomas |
| Q41868269 | The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma. |
| Q42608320 | The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma |
| Q104567531 | The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma |
| Q38552173 | Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients. |
| Q35218651 | Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. |
| Q38153086 | When should FDG-PET be used in the modern management of lymphoma? |
Search more.